Triflupromazine: Difference between revisions
No edit summary |
m (Protected "Triflupromazine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
(No difference)
|
Latest revision as of 17:20, 20 August 2015
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a600010 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C18H19F3N2S |
Molar mass | 352.418 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Triflupromazine |
Articles |
---|
Most recent articles on Triflupromazine Most cited articles on Triflupromazine |
Media |
Powerpoint slides on Triflupromazine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Triflupromazine at Clinical Trials.gov Trial results on Triflupromazine Clinical Trials on Triflupromazine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Triflupromazine NICE Guidance on Triflupromazine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Triflupromazine Discussion groups on Triflupromazine Patient Handouts on Triflupromazine Directions to Hospitals Treating Triflupromazine Risk calculators and risk factors for Triflupromazine
|
Healthcare Provider Resources |
Causes & Risk Factors for Triflupromazine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Triflupromazine (Vesprin) is an antipsychotic medication of the phenothiazine class. Among different effects of triflupromazine indication for use of this drug is severe emesis. Due to its potential side effects (triflupromazine has higher risk for side effects than many other antipsychotics) it is not gold standard in antiemetic therapy.
Serious side effects of trifluproamzine can be akathisia and tardive dyskinesia as well as the rare, but potentially fatal, neuroleptic malignant syndrome.
References
- Pages with script errors
- Template:drugs.com link with non-standard subpage
- Articles with changed DrugBank identifier
- Articles with changed ChemSpider identifier
- Articles with changed KEGG identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical articles with unknown parameter in Infobox drug
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Phenothiazines
- Organofluorides
- Drug